Conference Coverage
4 days ago
Looking back at the 2025 EnVision Summitabout 1 month ago
IRIS Registry data mined for understanding of pediatric NKLatest News
Feb 09, 2026 | Commentary
Angiogenesis 2026: Continuous AI severity scoring could transform AMD monitoring
4DMT completes enrollment in 4FRONT-1, phase 3 trial of 4D-150 in AMD
Feb 09, 2026
PRIMA System: A major step in the battle against GA
Feb 09, 2026
Q&A: Optimizing the ocular surface for light adjustable lens technology
Feb 09, 2026
MeiraGTx Licenses complement-targeted geographic atrophy program from ZipBio
Feb 06, 2026
Advertisement
Shorts
0:48
Eichenbaum Acorns Preview: Impact of a podcast
3 hours ago
by
Jayanth Sridhar, MD(+2 more)
0:37
Eichenbaum Acorns Preview: Becoming a mentor
2 days ago
by
Jayanth Sridhar, MD(+2 more)
0:37
Eichenbaum Acorns Preview: Managing a retina podcast
3 days ago
by
Jayanth Sridhar, MD(+2 more)
1:08
Celebrating National Women Physicians Day - Part 3
6 days ago
by
Oluwatosin U. Smith, MD
0:52
Celebrating National Women Physicians Day - Part 2
6 days ago
by
Marguerite B. McDonald, MD, FACS
1:22
Celebrating National Women Physicians Day
6 days ago
by
Christina Y. Weng, MD, MBA, FASRS(+1 more)
0:43
Eichenbaum Acorns Preview: Jayanth Sridhar, MD, on creating a podcast
7 days ago
by
Jayanth Sridhar, MD(+2 more)
0:26
Instant iOpeners: Collaboration between specialties
20 days ago
by
Mary Qiu, MD(+1 more)
0:51
Instant iOpeners: Meeting a neovascular glaucoma patient for the first time
21 days ago
by
Mary Qiu, MD(+2 more)
1:36
Ophthalmology without OCT - Part 5
3 months ago
by
David A. Eichenbaum, MD, FASRS(+2 more)
Ophthalmology Times Digital Edition
Proactive strategies enhance comfort, adherence, and long-term glaucoma control
Concentric lens positioning of an adjustable lens helps avoid a late myopic shift.
Daniela Ferrara, MD, PhD, FASRS, FARVO, discusses how data from low- and middle-income countries can strengthen US trials, improve equity, and inform innovation as the field looks toward 2026.
Strategies for treatment intervals, drug selection, and patient expectations.
Panel examines drug mechanisms, patient factors, and strategies to optimize results.
This approach helps distinguish diseases associated with macular atrophy.
Insights for diagnosing and managing these visible changes across specialties.
Podcasts
Continuing Medical Education
Advertisement
All News
Advertisement
The 2025 program built on its evolving reputation as a multispecialty educational forum that successfully integrates ophthalmology and optometry, premium CME content, and a family-friendly format to foster professional growth without sacrificing work–life balance.
Andrew G. Lee, MD, and Drew Carey, MD, discuss how optic disc cupping after optic neuritis reflects nerve and ganglion cell thinning, not disease type, helping distinguish it from glaucoma.
Metformin, a common diabetes medication, may be associated with less development of intermediate age-related macular degeneration (AMD).
Family-friendly format empowers continuing education.
NYU Grossman’s Preeya Mehta, MD, and Jonathan S. Williams, MD, sit down with Mount Sinai’s Louis R. Pasquale, MD, to discuss long-term safety and efficacy data from a PreserFlo microshunt trial and the role of microshunts in glaucoma surgery.
Advertisement
Revisyon is described as a device-led therapy that applies specific wavelengths of low-level LED light to the crystalline lens through a non-invasive, in-clinic procedure.
Proactive strategies enhance comfort, adherence, and long-term glaucoma control
Andrew Tatham, MD, MBA, FRCOphth, FEBO, outlines the role of micro-invasive glaucoma surgery alongside established glaucoma procedures, focusing on safety, patient selection, and future directions.
AI is reshaping clinical practice in retinal imaging and workflow optimization, according to Priv.-Doz. Dr. med. Jan H. Terheyden, FEBO.
Advertisement
Advertisement
Trending on Ophthalmology Times - Clinical Insights for Eye Specialists
1
Q&A: Optimizing the ocular surface for light adjustable lens technology
2
PRIMA System: A major step in the battle against GA
3
MeiraGTx Licenses complement-targeted geographic atrophy program from ZipBio
4
4DMT completes enrollment in 4FRONT-1, phase 3 trial of 4D-150 in AMD
5